

CAPhO Symposium - You're Invited to...

The Evolving Treatment Goals in Polycythemia Vera: Beyond Hematocrit Control

Session Description:

Management of polycythemia vera (PV) continues to evolve as treatment goals expand beyond hematocrit control and symptom management toward long-term disease modification. This symposium will explore the evolving therapeutic landscape and emerging clinical evidence in PV, including findings from prospective studies of novel long-acting immunomodulatory therapies such as ropeginterferon alfa-2b.

Speakers:



Dr. Mohamed Elemery
MD, MSc, PhD, FRCP.Edin
Director of Stem Cell Transplant
and Cellular Therapy Program
Chair of Provincial Disease Site
Group for Myeloid Malignancies
Saskatoon Cancer Centre



Jill Lacey
Senior Hematology
Pharmacist
Saskatoon Cancer
Centre

Learning objectives:

At the end of this session, participants will be able to:

- Describe the evolving treatment landscape for PV, including goals beyond symptom control.
- Discuss clinical data supporting early intervention in low- and high-risk patients.
- Recognize the potential role of novel interferon therapies in disease modification.
- Compare safety and dosing characteristics of current treatment options.
- Identify practical considerations for initiating therapy, monitoring response, and navigating access.

Date: Friday, April 24, 2026

Time: 10:30am – 12:00pm

Location: TCU Place, Room TBA

Canadian Association of Pharmacy in Oncology Annual Meeting.
Please RSVP using the CAPhO Registration Site.